| Hazard Information | Back Directory | [Uses]
Neihulizumab (ALTB-168) is an immune checkpoint agonistic antibody that binds to human CD162 (PSGL-1), leading to downregulation of activated T-cells. Neihulizumab can be uesd for steroid-refractory acute graft-versus-host-disease (SR-aGVHD), psoriasis, psoriatic arthritis and ulcerative colitis research[1]. | [References]
[1] Sameem Abedin, et al. Experimental Pharmaceuticals for Steroid-Refractory Acute Graft-versus-Host Disease. J Exp Pharmacol. 2020 Nov 26;12:549-557. DOI:10.2147/JEP.S259290
[2] Sameem Abedin, et al. Neihulizumab (ALTB-168) in Patients with Steroid-Refractory Acute Graft-Versus-Host-Disease (SR-aGVHD) or Treatment-Refractory Acute Graft-Versus-Host-Disease (TR-aGVHD). Blood (2022) 140 (Supplement 1): 10495-10497. |
|
|